PDCD1 and allergic respiratory disease: Whereas PD-1 on the activated ILC2s has somewhat inhibitory effects upon the pool of activated ILC2s (76), the number of lung PD-1+ ILC2s stably increases and never reaches a plateau phase during chronic airway allergy induced by nasal papain treatments for 3 weeks (21).